New Australian patent for Patrys' Deoxymab 3E10 nanoparticle technology

Latest News

Therapeutic antibody development company Patrys (ASX:PAB) has announced the Australian patent titled 'Antibody-mediated Autocatalytic, Targeted Delivery of Nanocarrier to Tumors' has been granted.

The company said the patent covers its novel Deoxymab 3E10 nanoparticle technology - for example PAT-DX1-NP - and includes specific claims covering the use of several different types of nanoparticle carriers conjugated to Deoxymabs for both the diagnosis and treatment of multiple types of cancers.

According to CEO and managing director, Dr James Campbell, “Our PAT-DX1 antibody is unique in that it binds to the DNA that is released from many solid cancers which results from the high turnover of cells in solid tumours.

"This means it can be used as a targeting agent for a range of cancers, regardless of their type. We have combined this broad-spectrum, tumour-targeting approach with nanoparticles that are able to carry a payload anti-cancer drugs that are toxic to the cancer.

"This combination allows us to specifically deliver cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells in the body. Unusually for an antibody, PAT-DX1 is also able to cross the blood brain barrier (BBB), opening up the potential to use it in patients with glioblastoma (primary brain cancer) or metastases that have spread to the brain from other cancers such as breast cancer.

"Patrys believes that the tumour-agnostic nature of the PAT-DX1-NP technology positions it well for a range of therapeutic applications in difficult-to-treat cancers, and is actively exploring several of these.”

The company said the patent expands its intellectual property portfolio. Five patents covering the unconjugated form of PAT-DX1 have already been granted - one in each of Europe, Japan, China, and two in the US.

However, this is the first patent to be granted that covers the use of PAT-DX1 conjugated to a diverse range of nanocarriers that will allow the targeted delivery of anticancer drugs and imaging agents to multiple types of cancer.